Skip to main content

Table 4 Survival and progression-free survival from diagnosis, and parameters of KD initiation, KD duration during and after protocol treatment, time from KD start and KD end till death (all in months) and KD compliance

From: Treatment of glioblastoma multiforme with “classic” 4:1 ketogenic diet total meal replacement

Subject no. Group no. Age Overall survival1 Dx-KD start Study RX duration KD continued after study KD start-death KD start-MRI progression Compliance2
1 1 62 29.2 2.2 6 20 27 7.8 3
2 1 64 11 1.5 6 1 9.5 1.6 3
3 1 40 25.1 1.7 6 13.3 23.4 3.9 3
53 2 48 19 1.5 1 0 17.5 7.1 0
6 2 62 38.7 32.4 5 0 6.3 2.2 2
7 2 41 13.9 6.4 0.2 0 7.5 0.6 NA
8 2 41 30.1 10.2 6 0 19.9 3.8 2
  1. Only 7 patients who died are included in the survival analysis. Group 1, newly diagnosed GBM, with KD adjunctive treatment to XRT and temozolomide. Group 2, recurrent GBM, with recurrence/progression after XRT, temozolomide, and recurrence/continued progression on bevacizumab. All months are given to the nearest decimal point
  2. 1Overall survival = survival from diagnosis
  3. 2Compliance is rated on a scale of 0–3: 0 = none, 1 = partial-slight, 2 = partial-substantial, 3 = complete
  4. 3Study subject no. 4 was alive at the time of submission and was therefore not included in the survival analysis